Overview
- Natera reported a strong second quarter with revenue around $753 million and testing volume above 1 million units for the second straight quarter.
- Clinical MRD (minimal residual disease) testing volume rose about 56% year over year to roughly 283,000 tests while Signatera’s average selling price increased to about $1,275.
- Management raised full-year revenue guidance to $2.85 billion–$2.91 billion and reported a gross margin near 65%, signaling improving unit economics.
- Shares jumped after an analyst described the quarter as “blowout” and technical commentary from investor outlets noted the rally pushed the stock into a profit-taking zone.
- Natera won regulatory approval in Japan in June for colorectal cancer use of Signatera, which detects tiny fragments of tumor DNA to screen for recurrence, and investors will watch whether sustained demand, reimbursement gains, and international rollout keep volumes high.